Oral Gilenya for multiple sclerosis approved in Canada
Posted: Thu Mar 10, 2011 5:32 am
Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya™ (fingolimod), has received Notice of Compliance in Canada. Gilenya™ (fingolimod) is the first disease modifying oral therapy developed for the relapsing-remitting form of multiple sclerosis (MS) which is the most common type of the disease in adults.Unlike current therapies which all require daily or regular injections or infusions, Gilenya offers simple once daily oral dosing (0.5 mg) in a capsule, providing an efficacious and convenient treatment method for a complex and lifelong illness. Gilenya is approved for use in patients who have tried one or more MS therapies, but are unresponsive or intolerant to them.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309